Asciminib (Bacrelba) is indicated for the treatment of adult patients with: Newly diagnosed or previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
Ph+ CML in CP harboring the T315I mutation.
Other Services
Country
Account